SeqOne Genomics Raises $20M to Propel AI-Powered Genomic Medicine Forward

SeqOne Genomics is thrilled to announce that it has successfully raised €20,000,000 in its latest funding round, marking a pivotal moment in the evolution of genomic medicine. As a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases, SeqOne continues to push the boundaries of what is possible in personalized medicine. This substantial investment is a strong testament from renowned investors such as Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club, who recognize the transformative power of SeqOne’s cutting-edge technology. The funds will be strategically deployed to scale and enhance the cloud-based SeqOne Platform—a CE-IVD Class C certified solution under the IVDR—which has already been acclaimed for its capacity to convert complex genomic data into fast, precise, and actionable insights. With this infusion of capital, the company aims to further empower molecular laboratories around Europe, enabling them to deliver life-saving diagnoses and tailored treatments more efficiently than ever before. This crucial funding will drive research and development initiatives, support advanced clinical validations, and expand the platform’s reach to additional molecular laboratories and institutions globally. With accolades such as the iLab award, the ARC Cancer Foundation’s Hélène Stark prize, and nominations for the esteemed Prix Galien award, SeqOne’s proven track record underlines its commitment to excellence and innovation in genomic medicine. By accelerating the development of AI solutions in healthcare, SeqOne is not just enhancing diagnostic precision but is also setting a new standard in the industry—a future where personalized medicine is accessible to every patient, everywhere.